Atosiban acetate is a Protein drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated in premature birth. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Antocin acetate, Atosiban Acetate Salt and yrrolidine-2-carboxamide acetate. Its PubChem CID is 87665603.
Atosiban acetate
| CAS No | 914453-95-5 |
|---|---|
| Molecular Formula | C45H71N11O14S2 |
| Molecular Weight | 1054.2 g/mol |
| Synonyms | acetic acid;(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Atosiban acetate is a Protein drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated in premature birth. The directory classifies it as a commercial API with a peptide source/manufacturing origin.
The listed CAS number is 914453-95-5.
The listed molecular formula is C45H71N11O14S2.
The listed molecular weight is 1054.2 g/mol.
acetic acid;(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide.
The source lists Antocin acetate, Atosiban Acetate Salt and yrrolidine-2-carboxamide acetate.